Edition:
United States

bluebird bio Inc (BLUE.OQ)

BLUE.OQ on NASDAQ Stock Exchange Global Select Market

78.70USD
26 May 2017
Change (% chg)

$-1.10 (-1.38%)
Prev Close
$79.80
Open
$79.75
Day's High
$81.50
Day's Low
$78.20
Volume
197,188
Avg. Vol
218,660
52-wk High
$100.40
52-wk Low
$36.62

Select another date:

Wed, May 3 2017

BRIEF-Bluebird bio Q1 total revenue $6.8 million

* Bluebird bio reports first quarter 2017 financial results and recent operational progress

BRIEF-Bluebird Bio entered into a worldwide license agreement around its proprietary lentiviral vector platform with Novartis Pharma

* Bluebird bio inc- entered into a worldwide license agreement around its proprietary lentiviral vector platform with novartis pharma ag

BRIEF-Bluebird Bio enters into patent license agreement with Glaxosmithkline for commercialization of Gene Therapies

* Bluebird bio enters lentiviral vector patent license agreement with Glaxosmithkline for commercialization of gene therapies

BRIEF-Bluebird Bio CEO's 2016 compensation was $4.9 mln

* CEO Nick Leschly's 2016 total compensation was $4.9 million versus $11.2 million in 2015 - sec filing Source text - http://bit.ly/2pmsOYK Further company coverage:

BRIEF-Bluebird Bio announces clinical, biological outcomes

* Announces clinical and biological outcomes for first patient with sickle cell disease treated with gene therapy

BRIEF-Bluebird bio qtrly net loss per share $1.88

* Bluebird Bio reports fourth quarter and full year 2016 financial results and recent operational progress

Medigene eyeing more immunotherapy deals after Bluebird pact

FRANKFURT German biotech firm Medigene said it is drawing more interest from prospective alliance partners for its technology to boost the immune response to cancer after its deal with U.S. peer Bluebird Bio.

Bluebird, Celgene myeloma treatment impresses in tiny study

Patients who previously were not helped by repeated treatments for multiple myeloma showed strong benefits from a new type of therapy in a small study, and with no worrisome side effects, drugmaker Bluebird Bio Inc said on Wednesday.

Select another date:

More From Around the Web